Passive Immunization against Congenital Cytomegalovirus Infection: Current State of Knowledge

Primary infection with the human cytomegalovirus (CMV) occurs in 1–4% of pregnancies. The rates of maternal-fetal CMV transmissions are around 25, 36, 41, and 66%, for infections occurring in the peri-conceptional weeks, first, second, and third trimester of pregnancy, respectively. On the other hand, the severity of fetal organ damage and dysfunction diminishes with increasing gestational age. Congenitally CMV-infected newborns may have neurosensory impairments like mental retardation, cerebral palsy, epilepsy, progressive hearing loss or visual defects, or even may have a fatal outcome. In in-vitro experiments, CMV specific neutralizing IgG antibodies – which are abundant in CMV specific hyperimmune globulin (HIG) products – inhibited the entry of the virus into target cells and hampered viral cell-to-cell spread. This article provides a brief overview on the epidemiology and diagnostic tools in congenital CMV infection. It also concisely summarizes the currently available study results on the safety and effectiveness of HIG treatment. Accordingly, in clinical studies HIG administration to expectant mothers following primary CMV infection (prophylactic use) was shown to lower the risk of maternal-fetal transmission of CMV compared to untreated controls. HIG was also able to Received: March 5, 2015 Accepted: March 9, 2015 Published online: April 25, 2015 Friederike Traunmüller, MD J&P Medical Research Ltd. Mooslackengasse 17 AT–1190 Vienna (Austria) E-Mail friederike.traunmueller @ jp-medical-research.com © 2015 S. Karger AG, Basel 0031–7012/15/0956–0209$39.50/0